BAX · available-data snapshot
Baxter International Inc. (BAX): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Baxter International Inc. (BAX); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for BAX?
We do not publish a fair value for Baxter International Inc.. What we can say from its filings and market data is below.
What is BAX's TickerWorth Score?
Cheap against our estimate — but a weaker business
Compared with Healthcare companies in US
Its strongest point: looks cheap on the numbers. Its weakest: balance sheet looks stretched.
- Value · 83 of 100
Cheaper than 83% of Healthcare companies in US
- Price vs worth · 100 of 100
- Quality · 33 of 100
More profitable than 33% of Healthcare companies in US
- Financial health · 26 of 100
Financially stronger than 26% of Healthcare companies in US
- Growth · 54 of 100
Growing faster than 54% of Healthcare companies in US
- Momentum · 67 of 100
Outperformed 67% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $25.11
- Market cap
- $12,
979, 184, 640 - 52-week high
- $30.00
- 52-week low
- $15.73
- Currency
- USD
- Exchange
- NYSE
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Baxter International Inc. (BAX) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, BAX trades at a recent price of $25.11, a market capitalisation of about $12,979,184,640, sitting 66% of the way up its 52-week range ($15.73–$30.00), on the NYSE.
The standard alternative to a DCF is relative valuation — comparing BAX's trading multiples against a sector benchmark. Here that gives Fwd P/E of 12.3× (cheaper than the peer median of 17.5×); P/B of 2.1× (cheaper than the peer median of 7.8×); P/S of 1.1× (cheaper than the peer median of 6.2×); EV/EBITDA of 10.9× (cheaper than the peer median of 18.5×); Dividend yield of 0.2% (richer than the peer median of 2.4%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. BAX shows a price-to-book (P/B) of 2.09 and book value of $12.00 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. BAX is in an up-trend (price above both its 50- and 200-day averages), trading -16.3% from its 52-week high. Over the past year the stock is +9.3%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
BAX vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | BAX | Peer median | Read |
|---|---|---|---|
| Fwd P/E | 12.3× | 17.5× | cheaper than |
| P/B | 2.1× | 7.8× | cheaper than |
| P/S | 1.1× | 6.2× | cheaper than |
| EV/EBITDA | 10.9× | 18.5× | cheaper than |
| Dividend yield | 0.2% | 2.4% | richer than |
What does Baxter International Inc. do?
What does it do?
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It operates in the Medical Instruments & Supplies industry (Healthcare sector), headquartered in United States. The company employs roughly 37,500 people.
How does it make money?
The business turns $11.2B in annual revenue into profit. Out of every $100 of sales, about $14 is left as operating profit (operating margin of 14.4%), after a 34% gross margin on the products/services it sells. After all costs, taxes and interest, -9.3% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries moderate debt (1.6× equity), comfortably covers its short-term bills (1.9× current ratio), and is currently lossmaking.
BAX insider trading
We have no recent SEC Form 4 insider filings on file for Baxter International Inc.. Form 4 covers US-listed companies only.
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.